BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19

• Press Releases

  Medtronic begins U.S. commercial launch of the MiniMed™ 780G system with the Instinct sensor, made by Abbott

  December 3, 2025

   · 

  4 min read
• Press Releases

  Strand Therapeutics Appoints Jeb Keiper to Board of Directors

  December 3, 2025

   · 

  4 min read
• Press Releases

  Thryv Therapeutics Strengthens Senior Leadership Team with Appointment of Matt Killeen, PhD, as Chief Business Officer

  December 3, 2025

   · 

  3 min read
• Press Releases

  Procyrion Appoints Andrew Davis as Chief Commercial Officer

  December 3, 2025

   · 

  3 min read
• Press Releases

  Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies

  December 3, 2025

   · 

  3 min read
• Press Releases

  Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium

  December 3, 2025

   · 

  5 min read
• Press Releases

  Aera Therapeutics to Present Preclinical Data on AERA-109, a Targeted In Vivo CAR-T Therapy for B Cell-mediated Autoimmune Diseases, at the 67th American Society of Hematology (ASH) Annual Meeting

  December 3, 2025

   · 

  2 min read
• Press Releases

  Eikon Therapeutics Announces the Election of David W. Meline to its Board of Directors

  December 3, 2025

   · 

  2 min read
• Press Releases

  Tenpoint Therapeutics, Ltd. to Participate in Upcoming December 2025 Investor Conference

  December 3, 2025

   · 

  1 min read
• Press Releases

  AOB Pharma receives European Medicines Agency (EMA) positive decision on the pediatric investigation plan (PIP), supporting future development of B244 for the treatment of mild to moderate atopic dermatitis in children, adolescents, and adults in the European Union (EU)

  December 3, 2025

   · 

  5 min read